Nathan J Bowen to Male
This is a "connection" page, showing publications Nathan J Bowen has written about Male.
Connection Strength
0.073
-
Li X, Chen Y, Bai L, Zhao R, Wu Y, Xie ZR, Wu JM, Bowen NJ, Danaher A, Cook N, Li D, Qui M, Du Y, Fu H, Osunkoya AO, Kucuk O, Wu D. Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models. Br J Cancer. 2023 09; 129(5):884-894.
Score: 0.016
-
Dougan J, Hawsawi O, Burton LJ, Edwards G, Jones K, Zou J, Nagappan P, Wang G, Zhang Q, Danaher A, Bowen N, Hinton C, Odero-Marah VA. Proteomics-Metabolomics Combined Approach Identifies Peroxidasin as a Protector against Metabolic and Oxidative Stress in Prostate Cancer. Int J Mol Sci. 2019 Jun 21; 20(12).
Score: 0.012
-
Elliott B, Millena AC, Matyunina L, Zhang M, Zou J, Wang G, Zhang Q, Bowen N, Eaton V, Webb G, Thompson S, McDonald J, Khan S. Essential role of JunD in cell proliferation is mediated via MYC signaling in prostate cancer cells. Cancer Lett. 2019 04 28; 448:155-167.
Score: 0.012
-
Burton LJ, Hawsawi O, Loyd Q, Henderson V, Howard S, Harlemon M, Ragin C, Roberts R, Bowen N, Gacii A, Odero-Marah V. Association of Epithelial Mesenchymal Transition with prostate and breast health disparities. PLoS One. 2018; 13(9):e0203855.
Score: 0.011
-
Chinaranagari S, Sharma P, Bowen NJ, Chaudhary J. Prostate cancer epigenome. Methods Mol Biol. 2015; 1238:125-40.
Score: 0.009
-
Patel D, Knowell AE, Korang-Yeboah M, Sharma P, Joshi J, Glymph S, Chinaranagari S, Nagappan P, Palaniappan R, Bowen NJ, Chaudhary J. Inhibitor of differentiation 4 (ID4) inactivation promotes de novo steroidogenesis and castration-resistant prostate cancer. Mol Endocrinol. 2014 Aug; 28(8):1239-53.
Score: 0.008
-
Matyunina LV, Bowen NJ, McDonald JF. LTR retrotransposons and the evolution of dosage compensation in Drosophila. BMC Mol Biol. 2008 Jun 04; 9:55.
Score: 0.006